Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial

BACKGROUND: Regarding the COVID-19 pandemic, potential therapeutic agents are being evaluated almost every day. Ciclosporin, a calcineurin inhibitor, is characterized by beneficial antiviral and immunomodulatory effects. The present study aimed to evaluate the efficacy of ciclosporin in managing COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Barati, Saghar, MohammadReza Hashemian, Seyed, Tabarsi, Payam, Abedini, Atefeh, Ashrafzadeh, Mahshid, Haseli, Sara, Abtahian, Zahra, Yousefian, Sahar, Dastan, Alireza, Sobhanian, Ali, Dastan, Farzaneh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332739/
https://www.ncbi.nlm.nih.gov/pubmed/34426105
http://dx.doi.org/10.1016/j.intimp.2021.108043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332739/
https://www.ncbi.nlm.nih.gov/pubmed/34426105
http://dx.doi.org/10.1016/j.intimp.2021.108043

Ejemplares similares